Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 19c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $2.56, $0.19 worse than the analyst estimate of $2.75. Revenue for the quarter came in at $394.4 million versus the consensus estimate of $410.82 million.

"Thus far, 2017 has been a highly productive year. We have executed on and delivered results of key clinical development programs, advanced multiple global regulatory efforts and received U.S. approval of Vyxeos for the treatment of adults with newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We continue to invest in our key products, product launches, R&D and corporate development activities to fuel our future growth and create long-term value."

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Exclusive: Axe Compute CEO says prepayments cover about a third of $3bn build cost
• Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at Needham